Skip to main content
SpringerLink
Log in

Positionspapier: Anwendung von Biologika bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem

Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNO-KHC)

  • Übersicht
  • Anwendung von Biologika bei CRSwNP
  • Published:
Allergo Journal Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A et al. Chronic rhinosinusitis in European underestimated disease. A GA²LEN study. Allergy 2011;66:1216-23

  2. Hirsch AG, Stewart WF, Sundaresan AS, Young AJ, Kennedy TL, Scott Greene J et al. Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample. Allergy 2017;72:274-81

  3. Ostovar A, Fokkens WJ, Vahdat K, Raeisi A, Mallahzadeh A, Farrokhi S. Epidemiology of chronic rhinosinusitis in Bushehr, southwestern region of Iran: a GA2LEN study. Rhinology 2019;57:43-8

  4. Shi JB, Fu QL, Zhang H, Cheng L, Wang YJ, Zhu DD et al. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy 2015;70:533-9

  5. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl 2012;23:3 p preceding table of contents, 1-298

  6. Stuck BA, Beule A, Jobst D, Klimek L, Laudien M, Lell M et al. [Guideline for "rhinosinusitis"-long version : S2k guideline of the German College of General Practitioners and Family Physicians and the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery]. HNO 2018;66:38-74

  7. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012;50:1-12

  8. Rosenfeld RM. Clinical practice guideline on adult sinusitis. Otolaryngol Head Neck Surg 2007;137:365-77

  9. Koennecke M, Klimek L, Mullol J, Gevaert P, Wollenberg B. Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities. Allergo J Int 2018;27:56-65

  10. Tomassen P, Vandeplas G, Van Zele T, Cardell L-O, Arebro J, Olze H et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol 2016;137:1449-56.e4

  11. Calus L, Van Zele T, Derycke L, Krysko O, Dutre T, Tomassen P et al. Local inflammation in chronic upper airway disease. Curr Pharm Des. 2012;18:2336-46

  12. Liao B, Liu JX, Li ZY, Zhen Z, Cao PP, Yao Y et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy 2018;73:1459-69

  13. Philpott CM, Erskine S, Hopkins C, Kumar N, Anari S, Kara N et al. Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. Respir Res 2018;19:129

  14. Wu D, Bleier BS, Li L, Zhan X, Zhang L, Lv Q et al. Clinical Phenotypes of Nasal Polyps and Comorbid Asthma Based on Cluster Analysis of Disease History. J Allergy Clin Immunol Pract 2018;6:1297-305 e1

  15. Khan A, Vandeplas G, Huynh TMT, Joish VN, Mannent L, Tomassen P et al. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology 2018;57:32-42

  16. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy 2016;9:45-53

  17. Lin DC, Chandra RK, Tan BK, Zirkle W, Conley DB, Grammer LC et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy 2011;25:205-8

  18. Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 2015;46:1308-21

  19. De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, Seys SF. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy 2017;7:22

  20. Seys SF, Scheers H, Van den Brande P, Marijsse G, Dilissen E, Van Den Bergh A et al. Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients. Respir Res 2017;18:39

  21. Zhang Y, Derycke L, Holtappels G, Wang XD, Zhang L, Bachert C et al. Th2 cytokines orchestrate the secretion of MUC5AC and MUC5B in IL-5-positive chronic rhinosinusitis with nasal polyps. Allergy 2018;74:131-40

  22. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-9

  23. GINA. Global Strategy for Asthma Management and Prevention (2019 update). www.ginasthma.org2019 Contract No.: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf

  24. Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Alt JA, Baroody FM et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol 2016;6 Suppl 1:S22-209

  25. Pundir V, Pundir J, Lancaster G, Baer S, Kirkland P, Cornet M et al. Role of corticosteroids in Functional Endoscopic Sinus Surgery--a systematic review and meta-analysis. Rhinology 2016;54:3-19

  26. Voorham J, Xu X, Price DB, Golam S, Davis J, Zhi Jie Ling J et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy 2018;74:273-83

  27. Kirsche H, Klimek L. ASS-Intoleranz-Syndrom und persistierende Rhinosinusitis: Differentialdiagnostik und Therapie. Hno 2015;63:357-63

  28. Klimek L, Pfaar O. Aspirin intolerance: does desensitization alter the course of the disease? Immunol Allergy Clin North Am 2009;29:669-75

  29. Kowalski ML, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Allergy 2019;74:28-39

  30. Hopkins C, Surda P, Bast F, Hettige R, Walker A, Hellings PW. Prevention of chronic rhinosinusitis. Rhinology 2018;56:307-15

  31. Kilty SJ, Lasso A, Mfuna-Endam L, Desrosiers MY. Case-control study of endoscopic polypectomy in clinic (EPIC) versus endoscopic sinus surgery for chronic rhinosinusitis with polyps. Rhinology 2018;56:155-7

  32. Rudmik L, Soler ZM, Hopkins C, Schlosser RJ, Peters A, White AA et al. Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Rhinology 2016;54:117-28

  33. Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol.2017;13:425-37

  34. Sanofi-Aventis_Deutschland_GmbH. Dupixent® 300 mg Injektionslösung in einer Fertigspritze, R.L.S. GmbH - Fachinformation. Rote Liste Service GmbH Frankfurt. 2020: p. 21.

  35. Annunziato F, Romagnani S. Heterogeneity of human effector CD4+ T cells. Arthritis Res Ther 2009;11:257

  36. Zygmunt B, Veldhoen M. T helper cell differentiation more than just cytokines. Adv Immunol 2011;109:159-96

  37. Kaur D, Brightling C. OX40/OX40 ligand interactions in T-cell regulation and asthma. Chest 2012;141:494-9

  38. Lane P. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells. J Exp Med 2000;191:201-6

  39. Plager DA, Kahl JC, Asmann YW, Nilson AE, Pallanch JF, Friedman O et al. Gene transcription changes in asthmatic chronic rhinosinusitis with nasal polyps and comparison to those in atopic dermatitis. PLoS One 2010;5:e11450

  40. Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van Cauwenberge P et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006;61:1280-9

  41. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Köhler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993;362:245-8

  42. Ouyang W, Ranganath SH, Weindel K, Bhattacharya D, Murphy TL, Sha WC et al. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 1998;9:745-55

  43. Danielsen A, Tynning T, Brokstad KA, Olofsson J, Davidsson A. Interleukin 5, IL6, IL12, IFN-gamma, RANTES and Fractalkine in human nasal polyps, turbinate mucosa and serum. Eur Arch Otorhinolaryngol 2006;263:282-9

  44. Derycke L, Eyerich S, Van Crombruggen K, Pérez-Novo C, Holtappels G, Deruyck N et al. Mixed T helper cell signatures in chronic rhinosinusitis with and without polyps. PloS one 2014;9:e97581

  45. Li Z, Zhang Y, Sun B. Current understanding of Th2 cell differentiation and function. Protein & cell. 2011;2:604-11

  46. Prussin C, Yin Y, Upadhyaya B. T(H)2 heterogeneity: Does function follow form? J Allergy Clin Immunol 2010;126:1094-8

  47. Bachert C, Wagenmann M, Hauser U, Rudack C. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 1997;99:837-42

  48. 48. Bachert C, Gevaert P, Holtappels G, Cuvelier C, van Cauwenberge P. Nasal polyposis: from cytokines to growth. Am J Rhinol 2000;14:279-90

  49. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001;14:705-14

  50. Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 2005;175:3463-8

  51. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003;24:25-9

  52. Peters AT, Kato A, Zhang N, Conley DB, Suh L, Tancowny B et al. Evidence for altered activity of the IL-6 pathway in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2010;125:397-403.e10

  53. Keswani A, Chustz RT, Suh L, Carter R, Peters AT, Tan BK et al. Differential expression of interleukin-32 in chronic rhinosinusitis with and without nasal polyps. Allergy 2012;67:25-32

  54. Chong LY, Head K, Hopkins C, Philpott C, Schilder AGM, Burton MJ. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst Rev 2016;4:CD011996

  55. Bai X, Kim SH, Azam T, McGibney MT, Huang H, Dinarello CA et al. IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages. J Immunol 2010;184:3830-40

  56. Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis. 2006;65 Suppl 3:iii61-4

  57. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005;22:131-42

  58. Li W, Sun W, Liu L, Yang F, Li Y, Chen Y et al. IL-32: a host proinflammatory factor against influenza viral replication is upregulated by aberrant epigenetic modifications during influenza A virus infection. J Immunol 2010;185:5056-65

  59. Netea MG, Azam T, Lewis EC, Joosten LA, Wang M, Langenberg D et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon-gamma-dependent mechanism. PLoS Med 2006;3:e277

  60. Nold MF, Nold-Petry CA, Pott GB, Zepp JA, Saavedra MT, Kim SH et al. Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol 2008;181:557-65

  61. Chin D, Harvey RJ. Nasal polyposis: an inflammatory condition requiring effective anti-inflammatory treatment. Curr Opin Otolaryngol Head Neck Surg 2013;21:23-30

  62. Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int 2015;64:121-30

  63. Lam EPS, Kariyawasam HH, Rana BMJ, Durham SR, McKenzie ANJ, Powell N et al. IL-25/IL-33-responsive TH2 cells characterize nasal polyps with a default TH17 signature in nasal mucosa. J Allergy Clin Immunol 2016;137:1514-24

  64. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008;223:20-38

  65. Reh DD, Wang Y, Ramanathan M, Jr., Lane AP. Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am J Rhinol Allergy 2010;24:105-9

  66. Kim D-K, Jin HR, Eun KM, Mo J-H, Cho SH, Oh S et al. The role of interleukin-33 in chronic rhinosinusitis. Thorax 2017;72:635-45

  67. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008;121:1484-90

  68. Castano R, Bosse Y, Endam LM, Desrosiers M. Evidence of association of interleukin-1 receptor-like 1 gene polymorphisms with chronic rhinosinusitis. Am J Rhinol Allergy 2009;23:377-84

  69. Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011;12:1055-62

  70. Robinette ML, Colonna M. Immune modules shared by innate lymphoid cells and T cells. J Allergy Clin Immunol 2016;138:1243-51

  71. Kim HY, Chang YJ, Subramanian S, Lee HH, Albacker LA, Matangkasombut P et al. Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J Allergy Clin Immunol 2012;129:216-27.e1-6

  72. Morita H, Moro K, Koyasu S. Innate lymphoid cells in allergic and nonallergic inflammation. J Allergy Clin Immunol 2016;138:1253-64

  73. Ho J, Bailey M, Zaunders J, Mrad N, Sacks R, Sewell W et al. Cellular comparison of sinus mucosa vs polyp tissue from a single sinus cavity in chronic rhinosinusitis. Int Forum Allergy Rhinol 2015;5:14-27

  74. Ho J, Bailey M, Zaunders J, Mrad N, Sacks R, Sewell W et al. Group 2 innate lymphoid cells (ILC2s) are increased in chronic rhinosinusitis with nasal polyps or eosinophilia. Clin Exp Allergy 2015;45:394-403

  75. Allen JS, Eisma R, LaFreniere D, Leonard G, Kreutzer D. Characterization of the eosinophil chemokine RANTES in nasal polyps. The Annals of otology, rhinology, and laryngology. 1998;107(5 Pt 1):416-20

  76. Beck LA, Stellato C, Beall LD, Schall TJ, Leopold D, Bickel CA et al. Detection of the chemokine RANTES and endothelial adhesion molecules in nasal polyps. J Allergy Clin Immunol 1996;98:766-80

  77. Meyer JE, Bartels J, Gorogh T, Sticherling M, Rudack C, Ross DA et al. The role of RANTES in nasal polyposis. Am J Rhinol 2005;19:15-20

  78. Davidsson A, Danielsen A, Viale G, Olofsson J, Dell'Orto P, Pellegrini C et al. Positive identification in situ of mRNA expression of IL-6, and IL-12, and the chemotactic cytokine RANTES in patients with chronic sinusitis and polypoid disease. Clinical relevance and relation to allergy. Acta Otolaryngol 1996;116:604-10

  79. Kato A, Peters A, Suh L, Carter R, Harris KE, Chandra R et al. Evidence of a role for B cell-activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2008;121:1385-92, 1392.e1-2

  80. Polzehl D, Moeller P, Riechelmann H, Perner S. Distinct features of chronic rhinosinusitis with and without nasal polyps. Allergy 2006;61:1275-9

  81. Patadia M, Dixon J, Conley D, Chandra R, Peters A, Suh LA et al. Evaluation of the presence of B-cell attractant chemokines in chronic rhinosinusitis. Am J Rhinol Allergy 2010;24:11-6

  82. Mehuys E, Gevaert P, Brusselle G, Van Hees T, Adriaens E, Christiaens T et al. Self-medication in persistent rhinitis: overuse of decongestants in half of the patients. J Allergy Clin Immunol Pract 2014;2:313-9

  83. Rudmik L, Soler ZM. Medical Therapies for Adult Chronic Sinusitis: A Systematic Review. Jama 2015;314:926-39

  84. 84. Smith TL, Sautter NB. Is montelukast indicated for treatment of chronic rhinosinusitis with polyposis? The Laryngoscope 2014;124:1735-6

  85. Stewart RA, Ram B, Hamilton G, Weiner J, Kane KJ. Montelukast as an adjunct to oral and inhaled steroid therapy in chronic nasal polyposis. Otolaryngol Head Neck Surg 2008;139:682-7

  86. Rondón C, Dávila I, Navarro Pulido AM, Sánchez MC, Montoro J, Matheu V et al. Clinical Management and Use of Health Care Resources in the Treatment of Nasal Polyposis in Spanish Allergy Centers: The POLAR Study. J Investig Allergol Clin Immunol 2015;25:276-82

  87. Wei CC, Adappa ND, Cohen NA. Use of topical nasal therapies in the management of chronic rhinosinusitis. Laryngoscope 2013;123:2347-59

  88. Head K, Chong LY, Hopkins C, Philpott C, Burton MJ, Schilder AGM. Short-course oral steroids alone for chronic rhinosinusitis. Cochrane Database Syst Rev 2016;4:CD011991

  89. Head K, Chong LY, Hopkins C, Philpott C, Schilder AGM, Burton MJ. Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011992

  90. Hox V, Lourijsen E, Jordens A, Aasbjerg K, Agache I, Alobid I et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy 2020;10:1

  91. Klimek L, Dollner R, Pfaar O, Mullol J. Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)? Curr Allergy Asthma Rep 2014;14:441

  92. Umbreit C, Virchow JC, Thorn C, Hörmann K, Klimek L, Pfaar O. Analgetikaintoleranz. Ein häufiges, interdisziplinäres Krankheitsbild. Aspirin-Intolerance-Syndrom. A common and interdisciplinary disease. Internist 2010;51:1196

  93. Weber R, Trautmann A, Randerath W, Heppt W, Hosemann W. ASS-Toleranzinduktion. Therapieoption bei Patienten mit analgetikainduzierter Erkrankung der Atemwege. Aspirin desensitization. Therapy options in patients with aspirin-exacerbated respiratory disease / CME-FRagebogen. Questionnaire. HNO 2012;60:369-83

  94. Comert S, Celebioglu E, Yucel T, Erdogan T, Karakaya G, Onerci M et al. Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease. Allergy 2013;68:1443-51

  95. Fruth K, Pogorzelski B, Schmidtmann I, Springer J, Fennan N, Fraessdorf N et al. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy 2013;68:659-65

  96. Rozsasi A, Polzehl D, Deutschle T, Smith E, Wiesmiller K, Riechelmann H et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 2008;63:1228-34

  97. Havel M, Ertl L, Braunschweig F, Markmann S, Leunig A, Gamarra F et al. Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad. Eur Arch Otorhinolaryngol 2013;270:571-8

  98. Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2007;119:157-64

  99. Rizk H. Role of aspirin desensitization in the management of chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 2011;19:210-7

  100. Renjiao L, Fengming L. The safety and efficacy of aspirin desensitization combined with long-term aspirin therapy in Aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol 2020;30:327-33

  101. A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps (SINUS-24) [database on the Internet]. Sanofi 2019. Accessed: 9.3.2020

  102. Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps (SINUS-52) [database on the Internet]. Sanofi. 2019. Accessed: 9.3.2020

  103. Mepolizumab in Nasal Polyposis. [database on the Internet] 2018. Accessed: 9.3.2020

  104. Effect of Mepolizumab in Severe Bilateral Nasal Polyps - EudraCT 2016-004255-70 [database on the Internet] 2019. Accessed: 9.3.2020

  105. A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps (POLYP 2) [database on the Internet]2019. Accessed: 9.3.2020

  106. A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps (POLYP 1) [database on the Internet]2019. Accessed: 9.3.2020

  107. Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis (OSTRO) [database on the Internet]. AstraZeneca. 2019. Accessed: 9.3.2020

  108. Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID) (ORCHID) [database on the Internet]. AstraZeneca. 2020. Accessed: 9.3.2020

  109. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM et al. Humanization of an antibody directed against IgE. Journal of immunology (Baltimore, Md : 1950). 1993;151:2623-32

  110. MacGlashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-45

  111. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90

  112. Novartis_Pharma_GmbH. Xolair ® 150 mg Injektionslösung, R.L.S. GmbH - Fachinformation. Rote Liste Service GmbH Frankfurt 2019:p. 9.

  113. Saini SS, Bindslev-Jensen C, Maurer M, Grob J-J, Bülbül Baskan E, Bradley MS et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015;135:67-75

  114. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013;131:110-6.e1

  115. Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol 2014;134:560-7.e4.

  116. Forster-Ruhrmann U, Stergioudi D, Pierchalla G, Fluhr JW, Bergmann KC, Olze H. Omalizumab in patients with NSAIDs-exacerbated respiratory disease. Rhinology 2020;58:226-32

  117. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019;394(10209):1638-50

  118. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. Jama 2016;315:469-79

  119. GlaxoSmithKline_GmbH_&_Co._KG. Nucala 100 mg Injektionslösung in einer Fertigspritze, R.L.S. GmbH - Fachinformation. Rote Liste Service GmbH Frankfurt. 2019: p. 6.

  120. Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. J Allergy Clin Immunol 2017;140:1024-31.e14

  121. AstraZeneca_GmbH. Fasenra ® 30 mg Injektionslösung in einer Fertigspritze, R.L.S. GmbH- Fachinformation. Rote Liste Service GmbH Frankfurt. 2019 p. 7

  122. Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis [database on the Internet]2019. Accessed: 9.3.2020

  123. Center HCaR. NAsal Polyps: Inflammatory & Molecular Phenotyping of Responders to Benralizumab (NAPPREB). 2019; https://clinicaltrials.gov/ct2/show/NCT04185012?term=NCT04185012&draw=2&rank=1.. Accessed 9.1.2020

  124. Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006;118:1133-41

  125. Teva_B._V. Cinqaero 10mg/ml, R.L.S. GmbH - Fachinformation. Rote Liste Service GmbH Frankfurt. 2018.

  126. Jacobs JS. Effect of Reslizumab in Chronic Rhinosinusitis. https://clinicaltrials.gov/ct2/show/NCT02799446?term=NCT02799446&draw=2&rank=1. 2018. Accessed 9.1.2020.

  127. Bachert C, Hellings PW, Mullol J, Hamilos DL, Gevaert P, Naclerio RM et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy 2020;75:148-57

  128. Liu T, Li TL, Zhao F, Xie C, Liu AM, Chen X et al. Role of thymic stromal lymphopoietin in the pathogenesis of nasal polyposis. The American journal of the medical sciences. 2011;341:40-7

  129. Kimura S, Pawankar R, Mori S, Nonaka M, Masuno S, Yagi T et al. Increased expression and role of thymic stromal lymphopoietin in nasal polyposis. Allergy Asthma Immunol Res 2011;3:186-93

  130. Nagarkar DR, Poposki JA, Tan BK, Comeau MR, Peters AT, Hulse KE et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol 2013;132:593-600 e12

  131. Gauvreau GM, Boulet LP, Cockcroft DW, FitzGerald JM, Mayers I, Carlsten C et al. OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy 2014;44:29-37

  132. Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014;370:2102-10

  133. Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther 2012;135:327-36

  134. Nutku E, Aizawa H, Hudson SA, Bochner BS. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003;101:5014-20

  135. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019;181:459-73

  136. Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol 2020;104:776-9

  137. Klimek L, Koennecke M, Hagemann J, Wollenberg B, Becker S. [Immunology of chronic rhinosinusitis with nasal polyps as a basis for treatment with biologicals]. HNO 2019;67:15-26

  138. De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, Seys SF. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy 2017;7:22

  139. Bachert C, Gevaert P, Hellings P. Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps. J Allergy Clin Immunol Pract 2017;5:1512-6

  140. Kim DW, Cho SH. Emerging Endotypes of Chronic Rhinosinusitis and Its Application to Precision Medicine. Allergy Asthma Immunol Res 2017;9:299-306

  141. Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 2019;74:2312-9

  142. Kim S-H, Han S-Y, Azam T, Yoon D-Y, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005;22:131-42

  143. Klimek L, Bergmann KC, Biedermann T, Bousquet J, Hellings P, Jung K et al. Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNO-KHC). Allergo J Int 2017;26:16-24

Download references

Author information

Authors and Affiliations

  1. FA für Dermatologie u. Allergologie, Zentrum f. Rhinologie und Allergologie, An den Quellen 10, 65183, Wiesbaden, Germany

    Ludger Klimek, Ulrike Förster-Ruhrmann, Sebastian Strieth,  Stefan Dazert & Achim G. Beule

  2. Universitätsklinik für Hals-, Nasen-, und Ohrenheilkunde, Universitätsklinik Tübingen, Elfriede-Aulhorn-Straße 5, 72076, Tübingen, Germany

    Sven Becker (Leitender Oberarzt / Stellvertretender Ärztlicher Direktor)

  3. Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Klinikum rechts der Isar - TU München, Ismaninger Str. 22, 81675, München, Germany

    Adam M. Chaker

  4. Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Ulm, Ulm, Germany

    Thomas K. Hoffmann

  5. Bonn, Germany

    Thomas Deitmer

  6. Berlin, Germany

    Heidi Olze

  7. Halle, Germany

    Alexander Glien

  8. Universitätsklinik und Poliklinik für Hals-Nasen-OhrenHeilkunde, Kopf- und Hals-Chirurgie, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Straße 40, 06097, Halle (Saale), Germany

    Stefan Plontke

  9. Hals-, Nasen- und Ohrenarzt, Herford, Germany

    Holger Wrede

  10. 60318, Frankfurt am Main, Germany

    Wolfgang W. Schlenter

  11. Hannover, Germany

    Hans-Jürgen Welkoborsky

  12. Freie Medizinjournalistin, München, Germany

    Barbara Wollenberg

  13. Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Münster, Münster, Germany

    Claudia Rudack

  14. Klinik für Hals-Nasen-Ohrenheilkunde, Universitätsklinikum Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany

    Martin Wagenmann

  15. Klinik für HNO-Heilkunde, Universitätsklinikum Frankfurt am Main, Frankfurt am Main, Germany

    Timo Stöver

  16. Department of Otorhinolaryngology, Head and Neck Surgery, Johannes Gutenberg-University, Mainz, Germany

    Tilman Huppertz

  17. - Universitätsmedizin Mainz -, Klinik f. Hals-Nasen-Ohrenheilkunde, Langenbeckstraße 1, 55131, Mainz, Germany

    Jan Hagemann

  18. UZ Gent - Kliniek voor Neus-, Keel- en Orheelkunde, De Pintelaan 185, 9000, Gent, Belgien

    Claus Bachert

Authors
  1. Ludger Klimek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrike Förster-Ruhrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sven Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adam M. Chaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sebastian Strieth
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thomas K. Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stefan Dazert
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Thomas Deitmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Heidi Olze
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Alexander Glien
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Stefan Plontke
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Holger Wrede
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Wolfgang W. Schlenter
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hans-Jürgen Welkoborsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Barbara Wollenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Achim G. Beule
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Claudia Rudack
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Martin Wagenmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Timo Stöver
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Tilman Huppertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Jan Hagemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Claus Bachert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ludger Klimek.

Ethics declarations

M. Wagenmann hat innerhalb der vergangenen 3 Jahre Honorare für Beratung, Vorträge oder Forschungsunterstützung von folgenden Firmen erhalten: ALK-Abelló, Allergopharma, AstraZeneca, Bencard Allergie, Genzyme, HAL Allergie, Infectopharm, LETI Pharma, MEDA Pharma, Novartis, Sanofi Aventis, Stallergenes, Teva - außerhalb der vorliegenden Arbeit.

B. Wollenberg hat Honorare und/oder Forschungsgelder von MSD, Sanofi, Astra Zeneca, Novartis und BMS Adboard erhalten - außerhalb der vorliegenden Arbeit.

J. Hagemann gibt an, Zuwendungen der Fa. Novartis Pharma GmbH für Vorträge erhalten zu haben.

C. Bachert erhielt Honorare und/oder Forschungsgelder von Sanofi, Novartis, GSL, Astra-Zeneca - außerhalb der vorliegenden Arbeit.

A. Chaker führt über die Technische Universität München Beratungsleistungen (z. B. Advisory Boards, DSMBs), Vorträge oder weitere Aktivitäten für Allergopharma, ALK-Abello, Astra Zeneca, GSK, HAL Allergy, Mundipharma, Nexter, Immunotek, Lofarma, SanofiGenzyme und Regeneron durch; hat klinische Studien oder Forschungsgelder über die Technische Universität München erhalten von ALK, Allergopharma, Astra Zeneca, Bencard/Allergen Therapeutics, ASIT Biotech, GSK, Novartis, Roche, und Zeller AG, ferner Forschungsmittel erhalten vom Umweltbundesamt der Bundesrepublik Deutschland, EIT Health und DZL (BMBF). A. Chaker hat ferner Honorare und Reisekostenerstattungen erhalten vom Bayerischen Ärzteblatt, der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI) und der European Academy of Allergy and Clinical Immunology (EAACI).

H. Olze erhielt Honorare und/oder Forschungsgelder von F. Hoffmann-La Roche Ltd, Sanofi-Aventis Deutschland, AstraZeneca und GlaxoSmithKline.

L. Klimek berichtet über Zuschüsse und/oder Honorare von Allergopharma, Novartis, MEDA/Mylan, HAL Allergie, ALK Abelló, LETI Pharma, Stallergenes, Quintiles, Sanofi, ASIT Biotech, Lofarma, Allergy Therapeut., AstraZeneca, GSK und Inmunotk - außerhalb der eingereichten Arbeit; und Mitgliedschaft bei folgenden Organisationen: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO-BV GPA, EAACI. L. Klimek ist Herausgeber des Allergo Journal.

U. Förster-Ruhrmann, W. Schlenter, S. Becker, A. G. Beule, S. Plontke, T. Deitmer, H. J. Welkoborsky, S. Dazert, C. Rudack, T. Huppertz, T. K. Hoffmann, A. Glien, S. Strieth, H. Wrede und T. Stöver haben keine Interessenkonflikte im Zusammenhang mit der vorliegenden Arbeit.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klimek, L., Förster-Ruhrmann, U., Becker, S. et al. Positionspapier: Anwendung von Biologika bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem. Allergo J 30, 24–44 (2021). https://doi.org/10.1007/s15007-021-4872-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15007-021-4872-z

Schlüsselwörter

Search

Navigation